ADMA Biologics Inc (ADMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has a cash flow conversion efficiency ratio of 0.072x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($29.54 Million) by net assets ($408.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ADMA Biologics Inc (ADMA) total market value for the company's overall valuation and market capitalisation.
ADMA Biologics Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ADMA Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADMA Biologics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of ADMA Biologics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
0.001x |
|
Mednax Inc
NYSE:MD
|
0.142x |
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
0.009x |
|
Ternium Argentina SA
BA:TXAR
|
0.014x |
|
Happy Forgings Limited
NSE:HAPPYFORGE
|
0.018x |
|
BeiJing DaHao Technology Co Lt
SHG:603025
|
0.051x |
|
Ningbo Huaxiang Electronic Co Ltd
SHE:002048
|
0.037x |
|
Foran Energy Group Co Ltd
SHE:002911
|
-0.014x |
Annual Cash Flow Conversion Efficiency for ADMA Biologics Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of ADMA Biologics Inc from 2006 to 2025. View ADMA share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $477.32 Million | $50.40 Million | 0.106x | -68.95% |
| 2024-12-31 | $349.02 Million | $118.67 Million | 0.340x | +422.41% |
| 2023-12-31 | $135.21 Million | $8.80 Million | 0.065x | +116.62% |
| 2022-12-31 | $151.97 Million | $-59.51 Million | -0.392x | +50.81% |
| 2021-12-31 | $141.17 Million | $-112.37 Million | -0.796x | +31.14% |
| 2020-12-31 | $88.25 Million | $-102.00 Million | -1.156x | +60.27% |
| 2019-12-31 | $26.19 Million | $-76.19 Million | -2.909x | +8.25% |
| 2018-12-31 | $19.77 Million | $-62.68 Million | -3.170x | -243.07% |
| 2017-12-31 | $40.33 Million | $-37.27 Million | -0.924x | -122.55% |
| 2016-12-31 | $-4.46 Million | $-18.27 Million | 4.099x | +121.82% |
| 2015-12-31 | $820.97K | $-15.42 Million | -18.781x | -667.40% |
| 2014-12-31 | $6.01 Million | $-14.70 Million | -2.447x | -384.94% |
| 2013-12-31 | $21.57 Million | $-10.89 Million | -0.505x | +31.11% |
| 2012-12-31 | $9.42 Million | $-6.90 Million | -0.733x | +92.99% |
| 2011-12-31 | $2.77K | $-29.00K | -10.458x | -118.39% |
| 2010-12-31 | $-346.00 | $-19.68K | 56.867x | -- |
| 2009-12-31 | $0.00 | $-24.46 Million | x | -- |
| 2008-12-31 | $0.00 | $-19.00 Million | x | -- |
| 2007-12-31 | $0.00 | $-23.61 Million | x | -- |
| 2006-12-31 | $0.00 | $-23.61 Million | x | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more